NCT02431559 2022-10-10Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian CancerLudwig Institute for Cancer ResearchPhase 1/2 Completed53 enrolled 22 charts
NCT01294293 2014-12-25TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerGOG FoundationPhase 1 Completed20 enrolled